Rejuvenate Bio Announces Partial Reprogramming Extends Lifespan
Rejuvenate Bio Announces Partnership with Leading Animal Health Company
Rejuvenate Bio Announces Preclinical Data for Gene Therapy Candidate RJB-0402 for the Treatment of Arrhythmogenic Cardiomyopathy
Like many other biotechs in this market environment, small gene therapy maker Rejuvenate Bio has struggled to rejuvenate its bank account.
SAN DIEGO--(BUSINESS WIRE)--Rejuvenate Bio, today announced new data for its gene therapy RJB-01 from a pilot study in canines with myxomatous mitral valve disease (MMVD), at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), held May 16-20, 2023, in Los Angeles, California.
Rejuvenate Bio Announces New Preclinical Research Evaluating Cellular Reprogramming for Age Reversal